Shots: The P-IIa POC OSCAR study involves assessing the efficacy and safety of otilimab (90mg, IV) + SOC vs PBO + SOC in 806 hospitalized adults with aged 18-79yrs. with […]readmore
Tags : Otilimab
Shots: GSK will initiate a clinical trial to evaluate its RA drug, otilimab on patients suffering from pneumonia related to COVID-19 at the end of May’2020. The study will evaluate […]readmore
Shots: The four P-III ContRAst -1, 2, 3 & X studies will assess otilimab (90mg/150mg, SC, qw) vs PBO, tofacitinib (5mg, bid), sarilumab (200mg, SC) all in combination with MTX/ […]readmore